Screening of gap junction antagonists on dye coupling in the rabbit retina.
Many cell types in the retina are coupled via gap junctions and so there is a pressing need for a potent and reversible gap junction antagonist. We screened a series of potential gap junction antagonists by evaluating their effects on dye coupling in the network of A-type horizontal cells. We evaluated the following compounds: meclofenamic acid (MFA), mefloquine, 2-aminoethyldiphenyl borate (2-APB), 18-alpha-glycyrrhetinic acid, 18-beta-glycyrrhetinic acid (18-beta-GA), retinoic acid, flufenamic acid, niflumic acid, and carbenoxolone. The efficacy of each drug was determined by measuring the diffusion coefficient for Neurobiotin (Mills & Massey, 1998). MFA, 18-beta-GA, 2-APB and mefloquine were the most effective antagonists, completely eliminating A-type horizontal cell coupling at a concentration of 200 muM. Niflumic acid, flufenamic acid, and carbenoxolone were less potent. Additionally, carbenoxolone was difficult to wash out and also may be harmful, as the retina became opaque and swollen. MFA, 18-beta-GA, 2-APB and mefloquine also blocked coupling in B-type horizontal cells and AII amacrine cells. Because these cell types express different connexins, this suggests that the antagonists were relatively non-selective across several different types of gap junction. It should be emphasized that MFA was water-soluble and its effects on dye coupling were easily reversible. In contrast, the other gap junction antagonists, except carbenoxolone, required DMSO to make stock solutions and were difficult to wash out of the preparation at the doses required to block coupling in A-type HCs. The combination of potency, water solubility and reversibility suggest that MFA may be a useful compound to manipulate gap junction coupling.
Pan
Feng
F
Department of Ophthalmology and Visual Science, University of Texas Medical School at Houston, Houston, Texas 77030, USA.
Mills
Stephen L
SL
Massey
Stephen C
SC
D000465:Algorithms; D000818:Animals; D001710:Biotin / Q000031:analogs & derivatives / Q000378:metabolism; D001896:Boron Compounds / Q000494:pharmacology; D004396:Coloring Agents; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004058:Diffusion; D004353:Drug Evaluation, Preclinical; D005260:Female; D017629:Gap Junctions / Q000187:drug effects*; D006034:Glycyrrhetinic Acid / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008297:Male; D008469:Meclofenamic Acid / Q000494:pharmacology; D015767:Mefloquine / Q000494:pharmacology; D018613:Microscopy, Confocal; D009415:Nerve Net / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D012160:Retina / Q000166:cytology / Q000187:drug effects*
D001896:Boron Compounds; D004396:Coloring Agents; D016861:Cyclooxygenase Inhibitors; C070614:neurobiotin; D008469:Meclofenamic Acid; D001710:Biotin; C035757:diphenylborate; D006034:Glycyrrhetinic Acid; D015767:Mefloquine
J Neurosci. 1982 Oct;2(10):1486-93
6181232
J Pharmacol Exp Ther. 2006 Dec;319(3):1452-8
16985167
J Neurocytol. 1990 Oct;19(5):731-6
1706416
Vis Neurosci. 1994 May-Jun;11(3):501-17
8038125
Vis Neurosci. 1994 May-Jun;11(3):549-60
7518689
Nature. 1995 Oct 26;377(6551):734-7
7477263
J Comp Neurol. 1996 Feb 26;366(1):15-33
8866843
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10942-7
11535816
J Membr Biol. 2002 Jan 15;185(2):93-102
11891568
Biol Chem. 2002 May;383(5):725-37
12108537
Neuron. 2002 Nov 14;36(4):703-12
12441058
Nat Rev Mol Cell Biol. 2003 Apr;4(4):285-94
12671651
J Vis. 2002;2(4):272-92
12678578
Mol Pharmacol. 2003 Jun;63(6):1389-97
12761350
J Neurosci. 2003 Nov 12;23(32):10249-57
14614083
Vis Neurosci. 2003 Jul-Aug;20(4):429-35
14658771
Cell Commun Adhes. 2003 Jul-Dec;10(4-6):425-30
14681052
J Comp Neurol. 2004 Feb 23;470(1):1-12
14755521
J Neurosci. 2004 Mar 31;24(13):3325-34
15056712
Eur J Neurosci. 2004 May;19(10):2633-40
15147297
J Neurosci. 2004 Jun 16;24(24):5632-42
15201336
J Neurophysiol. 2004 Aug;92(2):1252-6
15028741
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12364-9
15297615
J Neurosci. 1999 Nov 15;19(22):9848-55
10559394
Vis Neurosci. 1999 Sep-Oct;16(5):811-8
10580717
Vis Neurosci. 1999 Nov-Dec;16(6):1181-9
10614597
J Comp Neurol. 2000 Sep 18;425(2):193-201
10954839
J Neurosci. 2000 Nov 15;20(22):8629-36
11069972
J Neurosci. 2001 Jan 1;21(1):230-9
11150340
J Comp Neurol. 2001 Jul 30;436(3):336-50
11438934
Mol Pharmacol. 2001 Sep;60(3):541-52
11502886
J Pharmacol Exp Ther. 2001 Sep;298(3):1033-41
11504800
Proc R Soc Lond B Biol Sci. 1978 Dec 18;203(1152):229-45
84387
Proc R Soc Lond B Biol Sci. 1978 Dec 18;203(1152):247-67
84388
Vis Neurosci. 1997 May-Jun;14(3):565-76
9194323
Neurosci Lett. 1998 Feb 20;242(3):163-6
9530931
Vis Neurosci. 1998 Jul-Aug;15(4):765-77
9682877
J Neurosci. 1998 Dec 15;18(24):10594-602
9852595
J Physiol. 1999 Jun 15;517 ( Pt 3):673-89
10358109
J Neurosci. 2005 Jan 19;25(3):566-76
15659592
Biophys J. 2005 Mar;88(3):1725-39
15596513
J Neurophysiol. 2005 Mar;93(3):1476-85
15525810
Nat Rev Neurosci. 2005 Mar;6(3):191-200
15738956
Mol Pharmacol. 2005 Apr;67(4):1053-66
15598972
J Neurosci. 2005 Jul 13;25(28):6696-701
16014731
J Comp Neurol. 2005 Sep 12;490(1):29-39
16041717
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13313-8
16150718
J Comp Neurol. 2005 Nov 7;492(1):66-77
16175559
Vision Res. 2006 Feb;46(4):467-74
16023694
J Neurosci. 2006 Feb 8;26(6):1759-66
16467524
J Neurosci. 2006 Apr 19;26(16):4206-15
16624941
Eur J Neurosci. 2006 Sep;24(6):1675-86
17004931
J Neurosci. 2006 Nov 8;26(45):11624-36
17093084
J Membr Biol. 1985;84(3):269-83
4032457